Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.19 Insider Own7.80% Shs Outstand44.41M Perf Week28.77%
Market Cap630.18M Forward P/E- EPS next Y-2.72 Insider Trans4.53% Shs Float42.02M Perf Month-26.36%
Income-220.00M PEG- EPS next Q-1.30 Inst Own63.10% Short Float43.64% Perf Quarter25.58%
Sales1.30M P/S484.75 EPS this Y-53.40% Inst Trans-0.24% Short Ratio4.09 Perf Half Y-42.99%
Book/sh4.24 P/B3.35 EPS next Y37.30% ROA-94.30% Target Price18.73 Perf Year9.24%
Cash/sh4.33 P/C3.27 EPS next 5Y-0.20% ROE-129.50% 52W Range8.00 - 41.97 Perf YTD-63.22%
Dividend- P/FCF- EPS past 5Y0.00% ROI- 52W High-66.19% Beta1.61
Dividend %- Quick Ratio3.60 Sales past 5Y-46.80% Gross Margin- 52W Low77.37% ATR2.64
Employees270 Current Ratio3.60 Sales Q/Q4540.70% Oper. Margin- RSI (14)42.92 Volatility25.07% 12.03%
OptionableYes Debt/Eq0.12 EPS Q/Q-34.10% Profit Margin- Rel Volume2.38 Prev Close13.80
ShortableYes LT Debt/Eq0.08 EarningsMay 12 BMO Payout- Avg Volume4.48M Price14.19
Recom3.00 SMA20-26.10% SMA50-17.30% SMA200-47.82% Volume10,336,039 Change2.83%
Apr-29-16Downgrade Jefferies Hold → Underperform
Apr-26-16Reiterated RBC Capital Mkts Sector Perform $7.50 → $5
Apr-26-16Reiterated Needham Buy $53 → $20
Apr-26-16Downgrade Sun Trust Rbsn Humphrey Neutral → Reduce
Apr-26-16Downgrade Piper Jaffray Neutral → Underweight
Apr-22-16Reiterated RBC Capital Mkts Sector Perform $14 → $7.50
Mar-23-16Downgrade JMP Securities Mkt Perform → Mkt Underperform
Mar-01-16Reiterated Needham Buy $55 → $53
Jan-19-16Downgrade RBC Capital Mkts Outperform → Sector Perform $62 → $15
Jan-15-16Downgrade Piper Jaffray Overweight → Neutral
Oct-23-15Resumed BofA/Merrill Buy
Oct-23-15Initiated Jefferies Hold $28
Oct-02-15Reiterated Needham Buy $38 → $55
Aug-26-15Reiterated ROTH Capital Buy $50 → $45
Aug-26-15Reiterated ROTH Capital Buy $45 → $50
Aug-24-15Upgrade Piper Jaffray Neutral → Overweight $28 → $48
Aug-07-15Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
May-22-15Reiterated WBB Securities Strong Buy $25 → $35
May-21-15Downgrade BofA/Merrill Buy → Neutral
May-20-15Upgrade Sun Trust Rbsn Humphrey Neutral → Buy $14 → $33
May-01-16 10:55AM  5 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Apr-29-16 01:44PM  Will Sarepta Therapeutics (SRPT) Stock Be Hurt by Jefferies Downgrade? at TheStreet
12:41PM  Jefferies Cuts Sarepta To Sell, Sees Little Chance Of FDA Approval at Barrons.com
09:10AM  Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More at 24/7 Wall St.
09:00AM  Sarepta: FDA Policy Forced AdCom To Vote Against Patients' Interests at Forbes
07:01AM  Sarepta Therapeutics downgraded by Jefferies Briefing.com
12:37AM  [$$] Mental Dystrophy at the FDA at The Wall Street Journal
Apr-28-16 07:19PM  [$$] Mental Dystrophy at the FDA at The Wall Street Journal +19.48%
05:17PM  Sarepta Jumps On Hopes For Muscular Dystrophy Drug at Barrons.com
04:56PM  Is XBI Heading Back to Where It Started in April? Market Realist
02:35PM  Why Sarepta Therapeutics Inc. Is Up Big Today at Motley Fool
01:11PM  Why Are Investors Piling Into These Surging Stocks? at Insider Monkey
10:28AM  Jim Cramer -- Will FDA Approve Sarepta's Duchenne Drug After All? at TheStreet
10:17AM  Sarepta Can Win Speedy FDA Drug Approval at TheStreet
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead Zacks
09:27AM  Cramer's Mad Dash: Sarepta & PayPal CNBC
09:11AM  Sarepta Therapeutics shares surge 20% after article suggests drug approval possible at MarketWatch
Apr-27-16 04:07PM  Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News Zacks
10:17AM  Small Cap Watch: These 4 Stocks Are Making Big Moves Today Accesswire
09:35AM  These Five Stocks Could Be Ready To Double Heres Why! Accesswire
08:21AM  Despite Pleas, FDA Panel Shuns Drug at Motley Fool
07:20AM  More bad news for those that have this disease with no treatment at MarketWatch
Apr-26-16 07:15PM  Sarepta Shares Tumble Following FDA Committee's Decision Gurufocus -26.29%
04:04PM  The 52-Week Low Club for Tuesday at 24/7 Wall St.
03:03PM  [$$] Slim Sarepta Hopes Rest With Top FDA Official at Barrons.com
02:53PM  Stocks Are Mixed as Oil Jumps 3% at TheStreet
02:50PM  The right to try risky medical therapies CNBC
02:48PM  Analyst on FDA vs. Sarepta: Approval going against the od... CNBC
02:44PM  Patients' And Parents' Pleas Couldn't Trump Data Concerns At FDA Meeting On Muscular Dystrophy Drug at Forbes
02:41PM  Six Wall Street Analysts On What's Next For The Sarepta Duchenne Drug Story at Forbes
02:40PM  Parents' ability to turn their grief into good on display at Duchenne hearing at American City Business Journals
02:17PM  Here comes Apple, Twitter, and Chipotle Yahoo Finance
02:11PM  Why I'm Sticking With Sarepta at CNBC
01:16PM  Stocks Bide Time Ahead Of Fed; Apple Sluggish Pre-Earnings at Investor's Business Daily
12:36PM  Is This The Last Straw For Sarepta Therapeutics (SRPT) Stock? Zacks
12:30PM  Sarepta a wild stock 'not for everyone': Najarian CNBC
11:50AM  This Rare Childrens Disease Drug Is Pitting Patients Against the FDA at Fortune
11:46AM  Sarepta shares hammered CNBC
11:35AM  On the heels of bad news for Duchenne comes good news for Summit at American City Business Journals
11:31AM  FDA votes against Sarepta's DMD drug CNBC
11:29AM  Apple in focus; Sarepta Therapeutics sinks; Baxter earnings beat Yahoo Finance
11:27AM  Why Sarepta Therapeutics (SRPT) Stock Is Sharply Lower Today at TheStreet
11:17AM  Why You Should Watch These Five Stocks Today? at Insider Monkey
11:06AM  Why Sarepta Therapeutics, Allegheny Technologies, and Capital Product Partners Slumped This Morning at Motley Fool
10:06AM  Why Sarepta Therapeutics' Stock Is Crashing Today at Motley Fool
09:58AM  Here Are Three Ways To Prevent Tragic Battles Between The FDA And Patients at Forbes
09:56AM  FDA Panel's Recommendation Sends Sarepta's Shares Tumbling at The Wall Street Journal
09:45AM  Sarepta Therapeutics Tumbles On Multiple Downgrades After FDA Vote at Barrons.com
09:35AM  Biotech stock crashes 50% after disclosing bad news from the FDA Business Insider
08:02AM  Sarepta Therapeutics stock tanks after drug's FDA committee review at MarketWatch
07:02AM  FDA panel rejects Sarepta drug CNBC
12:48AM  FDA Panel Votes Not to Recommend Approval for Muscular Dystrophy Drug at The Wall Street Journal
Apr-25-16 09:05PM  U.S. panel: Sarepta Duchenne drug not proven effective Reuters
08:49PM  FDA Panel Votes Not to Recommend Approval for Muscular Dystrophy Drug at The Wall Street Journal
08:43PM  FDA officials critical of Duchenne drug during contentious hearing at American City Business Journals
08:36PM  Muscular dystrophy drug falls short at high-stakes meeting AP
07:44PM  FDA panel says Sarepta's Duchenne drug not proven effective at CNBC
07:35PM  Sarepta's CEO: Patient input matters CNBC
07:30PM  Votes by FDA drug panel dim hopes of fast approval of Duchenne drug at American City Business Journals
04:00PM  ETFs with exposure to Sarepta Therapeutics, Inc. : April 25, 2016 at Capital Cube
03:15PM  VRX vs. PRGO & SRPT vs the FDA CNBC
12:53PM  FDA chief lays out rationale for Duchenne drug to be granted temporary approval at American City Business Journals
11:55AM  Families Plead for FDA Advisers to Recommend Sarepta Muscle Drug at Bloomberg
07:46AM  FDA votes on muscular dystrophy drug CNBC
07:34AM  Sarepta Therapeutics FDA Panel Live Blog at TheStreet
Apr-24-16 12:46PM  An Investors' Guide to Sarepta's Eteplirsen FDA Advisory Panel Meeting at TheStreet
10:35AM  4 Companies That Have Destroyed Shareholders at 24/7 Wall St.
10:10AM  Why Key Analyst Sees Huge Upside in Sarepta Therapeutics at 24/7 Wall St.
Apr-22-16 04:17PM  Why Sarepta Therapeutics Inc. Is Bouncing Back Today at Motley Fool +35.66%
01:20PM  Duchenne moms undeterred: 'These boys are not precedents' at American City Business Journals
08:34AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : April 22, 2016 at Capital Cube
08:31AM  Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics? at TheStreet
Apr-21-16 06:05PM  Why Las Vegas Sands, Sarepta Therapeutics, and United Continental Holdings Slumped Today at Motley Fool -44.09%
03:26PM  Why Is Sarepta Therapeutics (SRPT) Stock Plunging Today? Zacks
02:21PM  [$$] Sarepta's Shares Drop After FDA Casts Doubts on Proposed Drug at The Wall Street Journal
01:25PM  Heres Why These 5 Stocks Are Deep in the Red Today at Insider Monkey
01:05PM  [$$] Sarepta Slammed by FDA, Stock Is Now Intriguing at Barrons.com
12:50PM  As Duchenne hearing takes shape, biotech world turns its focus to Washington at American City Business Journals
12:15PM  Down 41%: Is Sarepta Therapeutics Worth the Risk? at Motley Fool
11:58AM  The FDA's Muscular Dystrophy Debacle Shows Trying To Speed Drug Approvals Up Can Slow Them Down at Forbes
11:03AM  Sarepta Tumbles With Latest Comments From FDA at Forbes
10:35AM  Sarepta: That Really Wasn't Good at Barrons.com
10:02AM  Sarepta shares plummet after negative FDA outlook CNBC
09:58AM  FDA Still Negative on Sarepta's DMD Drug; Stock Price Sinks at TheStreet
09:50AM  Sarepta stock nuked by FDA outlook at CNBC
Apr-19-16 12:52PM  [Podcast] Biotech Analyst: Why revenue should be the focus for Q1 and how the upcoming election will impact names in the space -7.00%
11:35AM  Another Duchenne-focused biotech joins the Boston area biotech hub at bizjournals.com
07:59AM  7 Stocks Spiking on Big Volume at TheStreet
Apr-16-16 12:01AM  [$$] Showdown for Sarepta Therapeutics Shares at Barrons.com
Apr-15-16 06:00AM  Biotech Stock Mailbag: Sarepta Therapeutics' Big Event Is Coming at TheStreet
Apr-14-16 05:49PM  Three names to focus on in biotech
Apr-09-16 10:43AM  Why Sarepta Therapeutics Inc. Soared 44% Higher in March at Motley Fool
Apr-07-16 11:30AM  Why Sarepta Therapeutics Surged 20% in Wednesday Trading?
09:47AM  How investor is playing rally in Sarepta
Apr-06-16 04:27PM  Here's Why Sarepta Therapeutics Jumped Today at Motley Fool +19.30%
02:20PM  Street Talk: Wells Fargo, Cisco Systems, & more
12:41PM  Sarepta Therapeutics (SRPT) Stock Rising, Price Target Upped at Oppenheimer at TheStreet
Mar-31-16 08:48AM  Portola's APEX Trial Design Was Too Clever By Half at Forbes
Mar-25-16 11:25AM  Summit develops a unique Duchenne drug for any gene mutation at bizjournals.com
Mar-24-16 09:58AM  Biotech Stock Mailbag: How to Spot Red Flags in Clinical Trial Data at TheStreet
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company's lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; and a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BEHRENS M KATHLEENDirectorMar 16Buy14.5410,000145,43321,855Mar 16 08:15 PM
BEHRENS M KATHLEENDirectorMar 14Buy16.5465,0001,075,276112,166Mar 16 08:15 PM
Barry RichardDirectorMar 14Buy15.6675,0001,174,1853,241,014Mar 16 08:09 PM